NT PHARMA Reports Annual Results: Shareholder Loss Narrows by 51.2% to 26.041 Million Yuan

Stock News

Apr 01

NT PHARMA (01011) announced its annual results for the period ending December 31, 2025. The group recorded revenue of 24.158 million yuan, a decrease of 36.36% compared to the previous year. The loss attributable to the company's owners was 26.041 million yuan, representing a reduction of 51.2% year-on-year. The loss per share was 4.22 fen. According to the announcement, the group's traditional business continued to scale down during the review year. Meanwhile, its medical technology-related business remained in the asset preparation and compliance integration phase throughout 2025 and has not yet begun contributing to revenue.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1173749971"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1173749971\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1173749971?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-01 00:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1173749971","market":"sg","top_or_hot":-1,"title":"NT PHARMA Reports Annual Results: Shareholder Loss Narrows by 51.2% to 26.041 Million Yuan","media":"Stock News","content":"<p>NT PHARMA (01011) announced its annual results for the period ending December 31, 2025. The group recorded revenue of 24.158 million yuan, a decrease of 36.36% compared to the previous year. The loss attributable to the company's owners was 26.041 million yuan, representing a reduction of 51.2% year-on-year. The loss per share was 4.22 fen. According to the announcement, the group's traditional business continued to scale down during the review year. Meanwhile, its medical technology-related business remained in the asset preparation and compliance integration phase throughout 2025 and has not yet begun contributing to revenue.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>NT PHARMA Reports Annual Results: Shareholder Loss Narrows by 51.2% to 26.041 Million Yuan</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNT PHARMA Reports Annual Results: Shareholder Loss Narrows by 51.2% to 26.041 Million Yuan\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-04-01 00:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>NT PHARMA (01011) announced its annual results for the period ending December 31, 2025. The group recorded revenue of 24.158 million yuan, a decrease of 36.36% compared to the previous year. The loss attributable to the company's owners was 26.041 million yuan, representing a reduction of 51.2% year-on-year. The loss per share was 4.22 fen. According to the announcement, the group's traditional business continued to scale down during the review year. Meanwhile, its medical technology-related business remained in the asset preparation and compliance integration phase throughout 2025 and has not yet begun contributing to revenue.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1191","symbol_name":"制药","start_time":0,"source_url":"","article_id":"1173749971","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1173749971","pubTimestamp":1774973320,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"NT PHARMA (01011) announced its annual results for the period ending December 31, 2025. The group recorded revenue of 24.158 million yuan, a decrease of 36.36% compared to the previous year. The loss...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1191":"制药","01011":"泰凌医药"},"translate_title":"泰凌医药公布全年业绩：股东亏损收窄51.2%至2604.1万元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01011":1},"content_text":"NT PHARMA (01011) announced its annual results for the period ending December 31, 2025. The group recorded revenue of 24.158 million yuan, a decrease of 36.36% compared to the previous year. The loss attributable to the company's owners was 26.041 million yuan, representing a reduction of 51.2% year-on-year. The loss per share was 4.22 fen. According to the announcement, the group's traditional business continued to scale down during the review year. Meanwhile, its medical technology-related business remained in the asset preparation and compliance integration phase throughout 2025 and has not yet begun contributing to revenue.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}